Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: Transcriptional study in an animal model of hyperoxaluria

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 11, 2014, Pages

  Khan, Saeed R ^a   Joshi, Sunil ^a   Wang, Wei ^a   Peck, Ammon B ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Florida   (United States)

Author keywords

Fetuin; Kidney stone; Matrix Gla protein; Osteopontin; Reactive oxygen species

Indexed keywords

APOCYNIN; CALGRANULIN B; FETUIN B; FIBRONECTIN; HERMES ANTIGEN; HYDROXYPROLINE; OSTEOCALCIN; OSTEOPONTIN; PROTHROMBIN; REACTIVE OXYGEN METABOLITE; TAMM HORSFALL GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DATA BASE; EXPLANT; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; HYPEROXALURIA; IMMUNOHISTOCHEMISTRY; MACROMOLECULE; MALE; MICROARRAY ANALYSIS; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STONE FORMATION; UROLITHIASIS;

FETUIN; KIDNEY STONE; MATRIX GLA PROTEIN; OSTEOPONTIN; REACTIVE OXYGEN SPECIES;

ACETOPHENONES; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HYDROXYPROLINE; HYPEROXALURIA; KIDNEY; KIDNEY CALCULI; MALE; RATS; REACTIVE OXYGEN SPECIES;

EID: 84901707195     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00057.2014     Document Type: Article

References (85)

1. Asselman M, Verhulst A, Van Ballegooijen ES, Bangma CH, Verkoelen CF, De Broe ME. Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells. Kidney Int 68: 71-83, 2005.
2. Atmani F, Khan SR. Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients. Urol Int 68: 54-59, 2002.
3. Atmani F, Khan SR. Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J Am Soc Nephrol 10, Suppl 14: S385-S388, 1999.
4. Atmani F, Mizon J, Khan SR. Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-alpha-inhibitor. Eur J Biochem 236: 984-990, 1996.
5. Bergsland KJ, Kelly JK, Coe BJ, Coe FL. Urine protein markers distinguish stone-forming from non-stone-forming relatives of calcium stone formers. Am J Physiol Renal Physiol 291: F530-F536, 2006.
6. Beshensky AM, Wesson JA, Worcester EM, Sorokina EJ, Snyder CJ, Kleinman JG. Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol 12: 2108-2116, 2001.
7. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 376: 135-145, 2003.
8. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 7: 1475-1482, 1993.
9. Evan AP, Bledsoe SB, Smith SB, Bushinsky DA. Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int 65: 154-161, 2004.
10. Finlayson B, Khan SR, Hackett RL. Theoretical chemical models of urinary stone. In: Renal Tract Stone: Metabolic Basis and Clinical Practice, edited by Wickham JE, Buck AC. New York: Churchill Livingston, 1990, p. 133-147.
11. Gao B, Yasui T, Lu X, Zhou H, Liu J, Liu P, Okada A, Xiao C, Kohri K. Matrix Gla protein expression in NRK-52E cells exposed to oxalate and calcium oxalate monohydrate crystals. Urol Int 85: 237-241, 2010.
12. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97: 8010-8014, 2000.
13. Gokhale JA, Glenton PA, Khan SR. Characterization of Tamm-Horsfall protein in a rat nephrolithiasis model. J Urol 166: 1492-1497, 2001.
14. Gokhale JA, Glenton PA, Khan SR. Localization of tamm-horsfall protein and osteopontin in a rat nephrolithiasis model. Nephron 73: 456-461, 1996.
15. Gokhale JA, McKee MD, Khan SR. Immunocytochemical localization of Tamm-Horsfall protein in the kidneys of normal and nephrolithic rats. Urol Res 24: 201-209, 1996.
16. Grewal JS, Tsai JY, Khan SR. Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem J 387: 609-616, 2005.
17. Grover PK, Dogra SC, Davidson BP, Stapleton AM, Ryall RL. The prothrombin gene is expressed in the rat kidney: implications for urolithiasis research. Eur J Biochem 267: 61-67, 2000.
18. Grover PK, Miyazawa K, Coleman M, Stahl J, Ryall RL. Renal prothrombin mRNA is significantly decreased in a hyperoxaluric rat model of nephrolithiasis. J Pathol 210: 273-281, 2006.
19. Grover PK, Miyazawa K, Ryall RL. Renal prothrombin: quantification of mRNA using reverse transcription-polymerase chain reaction in a rat model. Electrophoresis 25: 797-803, 2004.
20. Grover PK, Ryall RL. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem 263: 50-56, 1999.
21. Hanna IR, Taniyama Y, Szocs K, Rocic P, Griendling KK. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 4: 899-914, 2002.
22. Hedgepeth RC, Yang L, Resnick MI, Marengo SR. Expression of proteins that inhibit calcium oxalate crystallization in vitro in the urine of normal and stone-forming individuals. Am J Kidney Dis 37: 104-112, 2001.
23. Herrmann M, Kinkeldey A, Jahnen-Dechent W. Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med 22: 197-201, 2012.
24. Hong SH, Lee HJ, Sohn EJ, Ko HS, Shim BS, Ahn KS, Kim SH. Anti-nephrolithic potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo. Pharmacol Rep 65: 970-979, 2013.
25. Hu T, Luan R, Zhang H, Lau WB, Wang Q, Zhang Y, Wang HC, Tao L. Hydrogen peroxide enhances osteopontin expression and matrix metalloproteinase activity in aortic vascular smooth muscle cells. Clin Exp Pharmacol Physiol 36: 626-630, 2009.
26. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009.
27. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Prot 4: 44-57, 2009.
28. Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int 93: 348-354, 2013.
29. Hunter GK, Grohe B, Jeffrey S, O'Young J, Sorensen ES, Goldberg HA. Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin. Cells Tissues Organs 189: 44-50, 2009.
30. 2+. Urol Res 31: 198-206, 2003.
31. Iida S, Peck AB, Byer KJ, Khan SR. Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. J Urol 162: 1480-1486, 1999.
32. Iida S, Peck AB, Johnson-Tardieu J, Moriyama M, Glenton PA, Byer KJ, Khan SR. Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 10: 986-996, 1999.
33. Jaggi M, Nakagawa Y, Zipperle L, Hess B. Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function. Urol Res 35: 55-62, 2007.
34. Joshi S, Saylor BT, Wang W, Peck AB, Khan SR. Apocynin-treatment reverses hyperoxaluria induced changes in NADPH oxidase system expression in rat kidneys: a transcriptional study. PLos One 7: e47738, 2012.
35. Khan A, Wang W, Khan SR. Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys. World J Urol 32: 123-130, 2014.
36. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8: 75-88, 2004.
37. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33: 349-357, 2005.
38. Khan SR. Nephrocalcinosis in animal models with and without stones. Urol Res 38: 429-438, 2010.
39. Khan SR. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189: 803-811, 2013.
40. Khan SR, Glenton PA, Byer KJ. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int 70: 914-923, 2006.
41. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA. Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol 168: 1173-1181, 2002.
42. Khan SR, Khan A, Byer KJ. Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol Dial Transplant 26: 1778-1785, 2011.
43. Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci 9: 1450-1482, 2004.
44. Kleinman JG, Beshensky A, Worcester EM, Brown D. Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 47: 1585-1596, 1995.
45. Kobayashi H, Shibata K, Fujie M, Sugino D, Terao T. Identification of structural domains in inter-alpha-trypsin involved in calcium oxalate crystallization. Kidney Int 53: 1727-1735, 1998.
46. Kohri K, Yasui T, Okada A, Hirose M, Hamamoto S, Fujii Y, Niimi K, Taguchi K. Biomolecular mechanism of urinary stone formation involving osteopontin. Urol Res 40: 623-637, 2012.
47. Kok DJ. Clinical implications of physicochemistry of stone formation. Endocrinol Metab Clin North Am 31: 855-867, 2002.
48. Li N, Yi FX, Spurrier JL, Bobrowitz CA, Zou AP. Production of superoxide through NADH oxidase in thick ascending limb of Henle's loop in rat kidney. Am J Physiol Renal Physiol 282: F1111-F1119, 2002.
49. Lieske JC, Hammes MS, Hoyer JR, Toback FG. Renal cell osteopontin production is stimulated by calcium oxalate monohydrate crystals. Kidney Int 51: 679-686, 1997.
50. Liu F, Wei CC, Wu SJ, Chenier I, Zhang SL, Filep JG, Ingelfinger JR, Chan JS. Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. Kidney Int 75: 156-166, 2009.
51. Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, Lieske JC, Wu XR. Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. Am J Physiol Renal Physiol 299: F469-F478, 2010.
52. Lyle AN, Joseph G, Fan AE, Weiss D, Landazuri N, Taylor WR. Reactive oxygen species regulate osteopontin expression in a murine model of postischemic neovascularization. Arterioscler Thromb Vasc Biol 32: 1383-1391, 2012.
53. Lyle AN, Remus EW, Fan AE, Lassegue B, Walter GA, Kiyosue A, Griendling KK, Taylor WR. Hydrogen peroxide regulates osteopontin expression through activation of transcriptional and translational pathways. J Biol Chem 289: 275-285, 2014.
54. Marengo SR, Chen DH, Kaung HL, Resnick MI, Yang L. Decreased renal expression of the putative calcium oxalate inhibitor Tamm-Horsfall protein in the ethylene glycol rat model of calcium oxalate urolithiasis. J Urol 167: 2192-2197, 2002.
55. Marengo SR, Resnick MI, Yang L, Chung JY. Differential expression of urinary inter-alpha-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men. J Urol 159: 1444-1450, 1998.
56. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin-a molecule for all seasons. QJM 95: 3-13, 2002.
57. McKee MD, Nanci A, Khan SR. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10: 1913-1929, 1995.
58. Miyake O, Yoshioka T, Yoshimura K, Honda M, Yamaguchi S, Koide T, Okuyama A. Expression of Tamm-Horsfall protein in stone-forming rat models. Br J Urol 81: 14-19, 1998.
59. Miyazawa K, Aihara K, Ikeda R, Moriyama MT, Suzuki K. cDNA macroarray analysis of genes in renal epithelial cells exposed to calcium oxalate crystals. Urol Res 37: 27-33, 2009.
60. Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol 293: F1935-F1943, 2007.
61. Moriyama MT, Glenton PA, Khan SR. Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 165: 1687-1692, 2001.
62. Mushtaq S, Siddiqui AA, Naqvi ZA, Rattani A, Talati J, Palmberg C, Shafqat J. Identification of myeloperoxidase, alpha-defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acta 384: 41-47, 2007.
63. Okada A, Nomura S, Higashibata Y, Hirose M, Gao B, Yoshimura M, Itoh Y, Yasui T, Tozawa K, Kohri K. Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection. Urol Res 35: 89-99, 2007.
64. Okada A, Yasui T, Fujii Y, Niimi K, Hamamoto S, Hirose M, Kojima Y, Itoh Y, Tozawa K, Hayashi Y, Kohri K. Renal macrophage migration and crystal phagocytosis via inflammatory-related gene expression during kidney stone formation and elimination in mice: Detection by association analysis of stone-related gene expression and microstructural observation. J Bone Miner Res 25: 2701-2711, 2010.
65. Okada A, Yasui T, Hamamoto S, Hirose M, Kubota Y, Itoh Y, Tozawa K, Hayashi Y, Kohri K. Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. J Bone Miner Res 24: 908-924, 2009.
66. Pillay SN, Asplin JR, Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol Renal Physiol 275: F255-F261, 1998.
67. Ryall RL. Macromolecules and urolithiasis: parallels and paradoxes. Nephron Physiol 98: p37-p42, 2004.
68. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357-366, 2003.
69. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 100: 593-603, 2008.
70. Stejskal D, Karpisek M, Vrtal R, Student V, Solichova P, Fiala R, Stejskal P. Urine fetuin-A values in relation to the presence of urolithiasis. BJU Int 101: 1151-1154, 2008.
71. Tardivel S, Medetognon J, Randoux C, Kebede M, Drueke T, Daudon M, Hennequin C, Lacour B. Alpha-1-microglobulin: inhibitory effect on calcium oxalate crystallization in vitro and decreased urinary concentration in calcium oxalate stone formers. Urol Res 27: 243-249, 1999.
72. Thongboonkerd V. Proteomics and kidney stone disease. Contrib Nephrol 160: 142-158, 2008.
73. Tsujihata M, Miyake O, Yoshimura K, Kakimoto KI, Takahara S, Okuyama A. Fibronectin as a potent inhibitor of calcium oxalate urolithiasis. J Urol 164: 1718-1723, 2000.
74. Tsujikawa K, Tsujihata M, Tei N, Yoshimura K, Nonomura N, Okuyama A. Elucidation of the mechanism of crystal-cell interaction using fibronectin-overexpressing Madin-Darby canine kidney cells. Urol Int 79: 157-163, 2007.
75. Umekawa T, Byer K, Uemura H, Khan SR. Diphenyleneiodium (DPI) reduces oxalate ion-and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol Dial Transplant 20: 870-878, 2005.
76. Umekawa T, Hatanaka Y, Kurita T, Khan SR. Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15: 635-644, 2004.
77. Umekawa T, Iguchi M, Uemura H, Khan SR. Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int 98: 656-660, 2006.
78. Umekawa T, Tsuji H, Uemura H, Khan SR. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 104: 115-120, 2009.
79. Verhulst A, Asselman M, Persy VP, Schepers MS, Helbert MF, Verkoelen CF, De Broe ME. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding-into a nonadherent epithelium. J Am Soc Nephrol 14: 107-115, 2003.
80. Verkoelen CF, Van Der Boom BG, Romijn JC. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int 58: 1045-1054, 2000.
81. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14: 139-147, 2003.
82. Wesson JA, Worcester EM, Kleinman JG. Role of anionic proteins in kidney stone formation: interaction between model anionic polypeptides and calcium oxalate crystals. J Urol 163: 1343-1348, 2000.
83. Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53: 952-957, 1998.
84. Yasui T, Fujita K, Sasaki S, Sato M, Sugimoto M, Hirota S, Kitamura Y, Nomura S, Kohri K. Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27: 255-261, 1999.
85. Zuo J, Khan A, Glenton PA, Khan SR. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol Dial Transplant 26: 1785-1796, 2011.